TW201328706A - 表皮生長因子受體３（ｈｅｒ３）之抗體 - Google Patents

Info

Publication number

TW201328706A

TW201328706A TW101145482A TW101145482A TW201328706A TW 201328706 A TW201328706 A TW 201328706A TW 101145482 A TW101145482 A TW 101145482A TW 101145482 A TW101145482 A TW 101145482A TW 201328706 A TW201328706 A TW 201328706A

Authority

TW

Taiwan

Prior art keywords

antibody

her3

group

inhibitor

fragment

Prior art date

2011-12-05

Links

• Espacenet
• Global Dossier
• Discuss

• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 title claims abstract description 521
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title claims abstract description 520
• 102000001301 EGF receptor Human genes 0.000 title claims description 48
• 108060006698 EGF receptor Proteins 0.000 title description 18
• 239000012634 fragment Substances 0.000 claims abstract description 219
• 239000003446 ligand Substances 0.000 claims abstract description 131
• 230000001419 dependent effect Effects 0.000 claims abstract description 60
• -1 e.g. Proteins 0.000 claims abstract description 34
• 230000014509 gene expression Effects 0.000 claims abstract description 27
• 230000001965 increasing effect Effects 0.000 claims abstract description 20
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 13
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 13
• 201000004101 esophageal cancer Diseases 0.000 claims abstract description 13
• 230000005764 inhibitory process Effects 0.000 claims abstract description 9
• 239000000427 antigen Substances 0.000 claims description 91
• 108091007433 antigens Proteins 0.000 claims description 90
• 102000036639 antigens Human genes 0.000 claims description 90
• 239000003814 drug Substances 0.000 claims description 90
• 229940124597 therapeutic agent Drugs 0.000 claims description 64
• 125000000539 amino acid group Chemical group 0.000 claims description 55
• 239000003112 inhibitor Substances 0.000 claims description 50
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 44
• 239000003795 chemical substances by application Substances 0.000 claims description 40
• 230000011664 signaling Effects 0.000 claims description 40
• 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 35
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 30
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 30
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 30
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 29
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 29
• 238000011282 treatment Methods 0.000 claims description 27
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 25
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 25
• 239000008194 pharmaceutical composition Substances 0.000 claims description 21
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims description 20
• 229960004891 lapatinib Drugs 0.000 claims description 19
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 17
• 229940124302 mTOR inhibitor Drugs 0.000 claims description 17
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 17
• 229940125497 HER2 kinase inhibitor Drugs 0.000 claims description 16
• 229960001972 panitumumab Drugs 0.000 claims description 16
• 229940094060 tykerb Drugs 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 15
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 15
• 229950002826 canertinib Drugs 0.000 claims description 14
• 229940116355 PI3 kinase inhibitor Drugs 0.000 claims description 13
• 230000002401 inhibitory effect Effects 0.000 claims description 13
• 201000009273 Endometriosis Diseases 0.000 claims description 12
• 229960001302 ridaforolimus Drugs 0.000 claims description 12
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
• 150000003384 small molecules Chemical group 0.000 claims description 11
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 10
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 9
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 9
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 9
• 229940082789 erbitux Drugs 0.000 claims description 9
• GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims description 9
• 206010017758 gastric cancer Diseases 0.000 claims description 9
• 238000007918 intramuscular administration Methods 0.000 claims description 9
• 238000007912 intraperitoneal administration Methods 0.000 claims description 9
• 229940084651 iressa Drugs 0.000 claims description 9
• 229950008001 matuzumab Drugs 0.000 claims description 9
• 229950008835 neratinib Drugs 0.000 claims description 9
• ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 9
• 201000011549 stomach cancer Diseases 0.000 claims description 9
• 229940120982 tarceva Drugs 0.000 claims description 9
• STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims description 8
• SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 claims description 8
• 229960001686 afatinib Drugs 0.000 claims description 8
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 8
• 229950010482 alpelisib Drugs 0.000 claims description 8
• 229950006418 dactolisib Drugs 0.000 claims description 8
• 229960002584 gefitinib Drugs 0.000 claims description 8
• 201000010536 head and neck cancer Diseases 0.000 claims description 8
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
• 238000007917 intracranial administration Methods 0.000 claims description 8
• 238000007913 intrathecal administration Methods 0.000 claims description 8
• 229950010203 nimotuzumab Drugs 0.000 claims description 8
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 8
• 229950008834 seribantumab Drugs 0.000 claims description 8
• 238000007920 subcutaneous administration Methods 0.000 claims description 8
• 229940100411 torisel Drugs 0.000 claims description 8
• 229960000575 trastuzumab Drugs 0.000 claims description 8
• 229960005395 cetuximab Drugs 0.000 claims description 7
• 239000003085 diluting agent Substances 0.000 claims description 7
• 229960005167 everolimus Drugs 0.000 claims description 7
• 229960002087 pertuzumab Drugs 0.000 claims description 7
• 238000007914 intraventricular administration Methods 0.000 claims description 6
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
• 229960002930 sirolimus Drugs 0.000 claims description 6
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
• 229960001320 lapatinib ditosylate Drugs 0.000 claims description 4
• AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 claims description 4
• 210000003238 esophagus Anatomy 0.000 claims description 3
• 235000020256 human milk Nutrition 0.000 claims description 2
• 239000000470 constituent Substances 0.000 claims 5
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 3
• 229960002428 fentanyl Drugs 0.000 claims 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
• 229960000598 infliximab Drugs 0.000 claims 1
• 229960003989 tocilizumab Drugs 0.000 claims 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
• 230000027455 binding Effects 0.000 abstract description 250
• 238000009739 binding Methods 0.000 abstract description 249
• 102000005962 receptors Human genes 0.000 abstract description 44
• 108020003175 receptors Proteins 0.000 abstract description 44
• 210000001519 tissue Anatomy 0.000 abstract description 17
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
• 230000019491 signal transduction Effects 0.000 abstract description 14
• 230000007423 decrease Effects 0.000 abstract description 12
• 201000010099 disease Diseases 0.000 abstract description 12
• 102000014413 Neuregulin Human genes 0.000 abstract description 10
• 108050003475 Neuregulin Proteins 0.000 abstract description 10
• 210000002307 prostate Anatomy 0.000 abstract description 8
• 210000000481 breast Anatomy 0.000 abstract description 6
• 206010003694 Atrophy Diseases 0.000 abstract description 5
• 230000037444 atrophy Effects 0.000 abstract description 5
• 208000035475 disorder Diseases 0.000 abstract description 3
• 230000016833 positive regulation of signal transduction Effects 0.000 abstract 1
• 241000282414 Homo sapiens Species 0.000 description 163
• 210000004027 cell Anatomy 0.000 description 148
• 238000000034 method Methods 0.000 description 140
• 108090000623 proteins and genes Proteins 0.000 description 137
• 235000018102 proteins Nutrition 0.000 description 110
• 102000004169 proteins and genes Human genes 0.000 description 110
• 125000003275 alpha amino acid group Chemical group 0.000 description 84
• 235000001014 amino acid Nutrition 0.000 description 80
• 229940024606 amino acid Drugs 0.000 description 72
• 150000001413 amino acids Chemical class 0.000 description 66
• 108090000765 processed proteins & peptides Proteins 0.000 description 66
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 62
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 62
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 62
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 62
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 61
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 53
• 102000004196 processed proteins & peptides Human genes 0.000 description 53
• 229920001184 polypeptide Polymers 0.000 description 49
• 206010028980 Neoplasm Diseases 0.000 description 48
• 150000007523 nucleic acids Chemical class 0.000 description 47
• 210000004602 germ cell Anatomy 0.000 description 39
• 238000012360 testing method Methods 0.000 description 38
• 230000000694 effects Effects 0.000 description 37
• 102000039446 nucleic acids Human genes 0.000 description 36
• 108020004707 nucleic acids Proteins 0.000 description 36
• 238000001994 activation Methods 0.000 description 35
• 230000004913 activation Effects 0.000 description 34
• 238000003556 assay Methods 0.000 description 32
• 238000002560 therapeutic procedure Methods 0.000 description 31
• 108060003951 Immunoglobulin Proteins 0.000 description 30
• 102000018358 immunoglobulin Human genes 0.000 description 30
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 29
• 230000003993 interaction Effects 0.000 description 29
• 230000035772 mutation Effects 0.000 description 29
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 28
• 239000000203 mixture Substances 0.000 description 28
• 230000001225 therapeutic effect Effects 0.000 description 25
• 238000004091 panning Methods 0.000 description 24
• 108010032595 Antibody Binding Sites Proteins 0.000 description 23
• 201000011510 cancer Diseases 0.000 description 23
• 230000004048 modification Effects 0.000 description 23
• 238000012986 modification Methods 0.000 description 23
• 239000013598 vector Substances 0.000 description 21
• 230000004927 fusion Effects 0.000 description 20
• 229920001223 polyethylene glycol Polymers 0.000 description 19
• 238000004458 analytical method Methods 0.000 description 18
• 229940079593 drug Drugs 0.000 description 18
• 239000013604 expression vector Substances 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 18
• 239000002202 Polyethylene glycol Substances 0.000 description 17
• 239000013078 crystal Substances 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 230000000069 prophylactic effect Effects 0.000 description 17
• 238000006467 substitution reaction Methods 0.000 description 17
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 16
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 16
• 238000004422 calculation algorithm Methods 0.000 description 16
• 102000037865 fusion proteins Human genes 0.000 description 16
• 108020001507 fusion proteins Proteins 0.000 description 16
• 239000002773 nucleotide Substances 0.000 description 16
• 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 15
• 241000699666 Mus <mouse, genus> Species 0.000 description 15
• 230000000295 complement effect Effects 0.000 description 15
• 238000006471 dimerization reaction Methods 0.000 description 15
• 239000007790 solid phase Substances 0.000 description 15
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 14
• 231100000599 cytotoxic agent Toxicity 0.000 description 14
• 102000057750 human ERBB3 Human genes 0.000 description 14
• 108020004705 Codon Proteins 0.000 description 13
• 230000013595 glycosylation Effects 0.000 description 13
• 238000006206 glycosylation reaction Methods 0.000 description 13
• 108091033319 polynucleotide Proteins 0.000 description 13
• 102000040430 polynucleotide Human genes 0.000 description 13
• 239000002157 polynucleotide Substances 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 108020004414 DNA Proteins 0.000 description 12
• 208000030270 breast disease Diseases 0.000 description 12
• 230000008859 change Effects 0.000 description 12
• 102000009027 Albumins Human genes 0.000 description 11
• 108010088751 Albumins Proteins 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 11
• 102400000058 Neuregulin-1 Human genes 0.000 description 11
• 108090000556 Neuregulin-1 Proteins 0.000 description 11
• 230000000890 antigenic effect Effects 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 231100000350 mutagenesis Toxicity 0.000 description 11
• 229920000642 polymer Polymers 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• 238000006366 phosphorylation reaction Methods 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 238000000746 purification Methods 0.000 description 10
• 238000012216 screening Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 241001529936 Murinae Species 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 108091000831 antigen binding proteins Proteins 0.000 description 9
• 102000025171 antigen binding proteins Human genes 0.000 description 9
• 230000000903 blocking effect Effects 0.000 description 9
• 239000002619 cytotoxin Substances 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 230000009977 dual effect Effects 0.000 description 9
• 230000026731 phosphorylation Effects 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 238000013268 sustained release Methods 0.000 description 9
• 239000012730 sustained-release form Substances 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 210000004899 c-terminal region Anatomy 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 229940050526 hydroxyethylstarch Drugs 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 125000005647 linker group Chemical group 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 230000009261 transgenic effect Effects 0.000 description 8
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
• 206010006187 Breast cancer Diseases 0.000 description 7
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• 241000588724 Escherichia coli Species 0.000 description 7
• 108091006905 Human Serum Albumin Proteins 0.000 description 7
• 102000008100 Human Serum Albumin Human genes 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 108091000080 Phosphotransferase Proteins 0.000 description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000037396 body weight Effects 0.000 description 7
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
• 238000002648 combination therapy Methods 0.000 description 7
• 238000013270 controlled release Methods 0.000 description 7
• 229940127089 cytotoxic agent Drugs 0.000 description 7
• 238000005734 heterodimerization reaction Methods 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 102000020233 phosphotransferase Human genes 0.000 description 7
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• 102000016359 Fibronectins Human genes 0.000 description 6
• 108010067306 Fibronectins Proteins 0.000 description 6
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
• 239000000443 aerosol Substances 0.000 description 6
• 239000012491 analyte Substances 0.000 description 6
• 125000004429 atom Chemical group 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 239000000833 heterodimer Substances 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 238000003127 radioimmunoassay Methods 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 238000002741 site-directed mutagenesis Methods 0.000 description 6
• 230000009870 specific binding Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 206010069754 Acquired gene mutation Diseases 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 102000019298 Lipocalin Human genes 0.000 description 5
• 108050006654 Lipocalin Proteins 0.000 description 5
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 230000008499 blood brain barrier function Effects 0.000 description 5
• 210000001218 blood-brain barrier Anatomy 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 238000012875 competitive assay Methods 0.000 description 5
• 230000001186 cumulative effect Effects 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 230000007783 downstream signaling Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 235000013922 glutamic acid Nutrition 0.000 description 5
• 229960002989 glutamic acid Drugs 0.000 description 5
• 239000004220 glutamic acid Substances 0.000 description 5
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
• 229910052737 gold Inorganic materials 0.000 description 5
• 239000010931 gold Substances 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 229940127121 immunoconjugate Drugs 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 201000005202 lung cancer Diseases 0.000 description 5
• 208000020816 lung neoplasm Diseases 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• 230000037439 somatic mutation Effects 0.000 description 5
• 230000006641 stabilisation Effects 0.000 description 5
• 238000011105 stabilization Methods 0.000 description 5
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
• 102000008102 Ankyrins Human genes 0.000 description 4
• 108010049777 Ankyrins Proteins 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 241000282836 Camelus dromedarius Species 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
• 108700019146 Transgenes Proteins 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 238000009295 crossflow filtration Methods 0.000 description 4
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
• 238000010494 dissociation reaction Methods 0.000 description 4
• 230000005593 dissociations Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 238000012377 drug delivery Methods 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 229940011871 estrogen Drugs 0.000 description 4
• 239000000262 estrogen Substances 0.000 description 4
• 230000001747 exhibiting effect Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 230000003472 neutralizing effect Effects 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 239000000700 radioactive tracer Substances 0.000 description 4
• 229940051022 radioimmunoconjugate Drugs 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000000717 retained effect Effects 0.000 description 4
• 230000007781 signaling event Effects 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 235000002198 Annona diversifolia Nutrition 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
• 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 101710112752 Cytotoxin Proteins 0.000 description 3
• 108010092160 Dactinomycin Proteins 0.000 description 3
• 102000009109 Fc receptors Human genes 0.000 description 3
• 108010087819 Fc receptors Proteins 0.000 description 3
• 102000002090 Fibronectin type III Human genes 0.000 description 3
• 108050009401 Fibronectin type III Proteins 0.000 description 3
• 238000012450 HuMAb Mouse Methods 0.000 description 3
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• 241000282838 Lama Species 0.000 description 3
• 241000282567 Macaca fascicularis Species 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 101800000675 Neuregulin-2 Proteins 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
• 206010038389 Renal cancer Diseases 0.000 description 3
• 238000011579 SCID mouse model Methods 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 108090000848 Ubiquitin Proteins 0.000 description 3
• 102000044159 Ubiquitin Human genes 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 201000000292 clear cell sarcoma Diseases 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 229960000975 daunorubicin Drugs 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 230000001687 destabilization Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 210000004696 endometrium Anatomy 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 201000010982 kidney cancer Diseases 0.000 description 3
• 201000007270 liver cancer Diseases 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 3
• 208000007538 neurilemmoma Diseases 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 210000002706 plastid Anatomy 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 230000004850 protein–protein interaction Effects 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 210000004872 soft tissue Anatomy 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 230000000087 stabilizing effect Effects 0.000 description 3
• 238000012289 standard assay Methods 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 229960003604 testosterone Drugs 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006179 Breast atrophy Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 102000005600 Cathepsins Human genes 0.000 description 2
• 108010084457 Cathepsins Proteins 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 101100437104 Drosophila melanogaster AttB gene Proteins 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 101800000155 Epiregulin Proteins 0.000 description 2
• 102400001329 Epiregulin Human genes 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
• 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 2
• 102000009490 IgG Receptors Human genes 0.000 description 2
• 108010073807 IgG Receptors Proteins 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 238000012449 Kunming mouse Methods 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000282842 Lama glama Species 0.000 description 2
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 241000713333 Mouse mammary tumor virus Species 0.000 description 2
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 241000255972 Pieris <butterfly> Species 0.000 description 2
• 229920002873 Polyethylenimine Polymers 0.000 description 2
• 229920000954 Polyglycolide Polymers 0.000 description 2
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
• 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• 241000710961 Semliki Forest virus Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical group OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
• 241000223259 Trichoderma Species 0.000 description 2
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 238000002441 X-ray diffraction Methods 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
• 239000000051 antiandrogen Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
• 229930195731 calicheamicin Natural products 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 239000000599 controlled substance Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 229960004199 dutasteride Drugs 0.000 description 2
• JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 229960004039 finasteride Drugs 0.000 description 2
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 230000033581 fucosylation Effects 0.000 description 2
• 238000002825 functional assay Methods 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 229910001385 heavy metal Inorganic materials 0.000 description 2
• 229940022353 herceptin Drugs 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
• 230000006651 lactation Effects 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229960004194 lidocaine Drugs 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 210000005075 mammary gland Anatomy 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 230000027939 micturition Effects 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000003032 molecular docking Methods 0.000 description 2
• 229920005615 natural polymer Polymers 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 238000006384 oligomerization reaction Methods 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 238000003566 phosphorylation assay Methods 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000007420 reactivation Effects 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 238000002424 x-ray crystallography Methods 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
• CBMYJHIOYJEBSB-KHOSGYARSA-N 5alpha-androstane-3alpha,17beta-diol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-KHOSGYARSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
• 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
• 102100038778 Amphiregulin Human genes 0.000 description 1
• 108010033760 Amphiregulin Proteins 0.000 description 1
• 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
• 230000005724 C-terminal phosphorylation Effects 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 101150058073 Calm3 gene Proteins 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• 241000282828 Camelus bactrianus Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 241000759568 Corixa Species 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 102000014824 Crystallins Human genes 0.000 description 1
• 108010064003 Crystallins Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
• 101100012878 Drosophila melanogaster htl gene Proteins 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 206010051909 Endometrial atrophy Diseases 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 108010014173 Factor X Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 102000000340 Glucosyltransferases Human genes 0.000 description 1
• 108010055629 Glucosyltransferases Proteins 0.000 description 1
• 102000017278 Glutaredoxin Human genes 0.000 description 1
• 108050005205 Glutaredoxin Proteins 0.000 description 1
• 102000051366 Glycosyltransferases Human genes 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000919395 Homo sapiens Aromatase Proteins 0.000 description 1
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical group C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 239000012515 MabSelect SuRe Substances 0.000 description 1
• 229930126263 Maytansine Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
• 240000002769 Morchella esculenta Species 0.000 description 1
• 235000002779 Morchella esculenta Nutrition 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 101800000673 Neuregulin-3 Proteins 0.000 description 1
• 101800002641 Neuregulin-4 Proteins 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical class NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
• 208000014174 Oesophageal disease Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 239000012828 PI3K inhibitor Substances 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 description 1
• 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 208000025844 Prostatic disease Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108020005067 RNA Splice Sites Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 101710192266 Tegument protein VP22 Proteins 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241001416176 Vicugna Species 0.000 description 1
• 108010087302 Viral Structural Proteins Proteins 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229960004607 alfuzosin Drugs 0.000 description 1
• WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• OQXCFOKEAFQNJL-UHFFFAOYSA-N amino diethyl phosphate Chemical compound CCOP(=O)(ON)OCC OQXCFOKEAFQNJL-UHFFFAOYSA-N 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000009830 antibody antigen interaction Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 108010044540 auristatin Proteins 0.000 description 1
• 230000002886 autophagic effect Effects 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000003235 crystal violet staining Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000011548 crystallization buffer Substances 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
• 238000011026 diafiltration Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• GOJNABIZVJCYFL-UHFFFAOYSA-N dimethylphosphinic acid Chemical compound CP(C)(O)=O GOJNABIZVJCYFL-UHFFFAOYSA-N 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 238000011833 dog model Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960001389 doxazosin Drugs 0.000 description 1
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 229960005501 duocarmycin Drugs 0.000 description 1
• 229930184221 duocarmycin Natural products 0.000 description 1
• VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 235000014103 egg white Nutrition 0.000 description 1
• 210000000969 egg white Anatomy 0.000 description 1
• 238000001211 electron capture detection Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 238000012407 engineering method Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 208000028299 esophageal disease Diseases 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000006277 exogenous ligand Substances 0.000 description 1
• 239000003777 experimental drug Substances 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 101150023212 fut8 gene Proteins 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• 102000013069 gamma-Crystallins Human genes 0.000 description 1
• 108010079934 gamma-Crystallins Proteins 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 230000010224 hepatic metabolism Effects 0.000 description 1
• 238000012203 high throughput assay Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000044018 human CYP19A1 Human genes 0.000 description 1
• 102000045108 human EGFR Human genes 0.000 description 1
• 102000051957 human ERBB2 Human genes 0.000 description 1
• 210000000688 human artificial chromosome Anatomy 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000008676 import Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 229910052741 iridium Inorganic materials 0.000 description 1
• GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000012633 leachable Substances 0.000 description 1
• HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 150000008146 mannosides Chemical class 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000000569 multi-angle light scattering Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• HFDUQFHISFSFBW-UHFFFAOYSA-N n',n'-dimethylbut-2-ene-1,4-diamine Chemical compound CN(C)CC=CCN HFDUQFHISFSFBW-UHFFFAOYSA-N 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 239000002539 nanocarrier Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 231100001223 noncarcinogenic Toxicity 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002902 organometallic compounds Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 230000006267 polysialylation Effects 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 229960001289 prazosin Drugs 0.000 description 1
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000035752 proliferative phase Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000007026 protein scission Effects 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000006432 protein unfolding Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 229940121896 radiopharmaceutical Drugs 0.000 description 1
• 230000002799 radiopharmaceutical effect Effects 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 230000033300 receptor internalization Effects 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000013878 renal filtration Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000035946 sexual desire Effects 0.000 description 1
• 238000012807 shake-flask culturing Methods 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000007755 survival signaling Effects 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960002613 tamsulosin Drugs 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960001693 terazosin Drugs 0.000 description 1
• VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 125000006169 tetracyclic group Chemical group 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000008427 tissue turnover Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000006208 topical dosage form Substances 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000012451 transgenic animal system Methods 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000001296 transplacental effect Effects 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 150000005671 trienes Chemical class 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1